Scott Harris

Company: Altimmune

Job title: Chief Medical Officer

Seminars:

Attaining Product Differentiation through Improved Patient Segmentation & Efficiency 1:30 pm

Understanding the differentiation in the marketplace as the treatment of obesity matures Focusing on market segmentation and patient phenotypes to develop suitable GLP-1s for individual patient needsRead more

day: Conference Day Two

Roundtable Discussion: Investigating the Inflation Reduction Act (IRA) to Clarify the Effect This Legislation Could Have on GLP-1s to Build Appropriate Plans for Your Pipeline 12:00 pm

Maximising understanding of the IRA to ensure you are informed regarding the timing and significance of this legislative framework Examining the impact of the IRA regarding GLP-1-based treatments to proactively anticipate changes that may be required Highlighting specific areas where this regulation could exert an impact and providing examples of how to align your GLP-1…Read more

day: Conference Day Two

Panel Discussion: Discussing the Future Indications of GLP-1-Based Therapeutics – Promises & Challenges 2:30 pm

Advancing the reach of GLP-1-based treatments into other therapeutic areas, particularly Alzheimer’s and Parkinson’s disease Exploring the scientific validity of the latest treatment frontiers with GLP-1s to understand the potential in these areas Considering the commercial possibilities of these new therapeutic area markets to grasp the scope of opportunityRead more

day: Conference Day One

Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease 10:00 am

Navigating the rationale behind using GLP-1s to treat MASH and fatty liver disease Understanding the limitations of GLP-1 monotherapy and GLP-1/GIP dual agonists and the therapeutic benefit of glucagon-based agentsRead more

day: Conference Day One